Back to discover
Disease

Inclusion body myositis

Late-stage therapeutic development
Also known as IBM, Sporadic Inclusion Body Myositis, sIBM, sporadic inclusion body myositis+2 more

IBM, Sporadic Inclusion Body Myositis, sIBM, sporadic inclusion body myositis, Ibm, inflammatory myopathy.

12
Clinical trials
5
Associated genes
1
Related proteins

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 2 clinical trials expected to report results, the earliest in Q4 2027.
Upcoming Milestones
Clinical Milestones3View
Results expected 2
Recently completed 1
Activity timeline3

Clinical trials

9 sponsors · 0 new · 1 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
12
All trials
3
Active
7
Late-stage
6
Completed
Late-stage studies

An Open-label, Multicenter Study to Evaluate the Long-term Safety and Efficacy of Ulviprubart (ABC008) in Subjects Who Have Completed a Trial of Ulviprubart for the Treatment of Inclusion Body Myositis

Phase 2/3 · Active, not recruiting · Abcuro, Inc.

A Double-Blind Randomised Controlled Trial (dbRCT) Phase III Trial Investigating the Effect of Sirolimus on Disease Progression in Patients With Inclusion Body Myositis (IBM) as Measured by the IBM Functional Rating Scale (IBM-FRS)

Phase 3 · Active, not recruiting · University of Kansas Medical Center

Extension of the CBYM338B2203 Phase IIb/III Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Intravenous BYM338 in Patients With Sporadic Inclusion Body Myositis

Phase 3 · Completed · Novartis Pharmaceuticals

An Open-label, Long-term Study to Evaluate the Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

Phase 2/3 · Completed · Novartis Pharmaceuticals

A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABC008 in the Treatment of Subjects With Inclusion Body Myositis

Phase 2/3 · Completed · Abcuro, Inc.

Étude de l'Effet de la Rapamycine Sur la Force Musculaire et la réponse Immunitaire au Cours de la Myosite à Inclusions: étude RAPAMI"

Phase 2/3 · Completed · Institut National de la Santé Et de la Recherche Médicale, France
Recruiting

Blocking Interferon-γ by Ruxolitinib for Treating Inclusion Body Myositis: a Phase IIb Trial

Phase 2 · Recruiting · Assistance Publique - Hôpitaux de Paris
Recently completed

A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABC008 in the Treatment of Subjects With Inclusion Body Myositis

Phase 2/3 · Completed · Abcuro, Inc.

An Open-Label Pilot Study of Pioglitazone in Sporadic Inclusion Body Myositis

Phase 1 · Completed · Johns Hopkins University

Étude de l'Effet de la Rapamycine Sur la Force Musculaire et la réponse Immunitaire au Cours de la Myosite à Inclusions: étude RAPAMI"

Phase 2/3 · Completed · Institut National de la Santé Et de la Recherche Médicale, France

Phase I Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis.

Phase 1 · Completed · Nationwide Children's Hospital

An Open-label, Long-term Study to Evaluate the Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

Phase 2/3 · Completed · Novartis Pharmaceuticals

Extension of the CBYM338B2203 Phase IIb/III Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Intravenous BYM338 in Patients With Sporadic Inclusion Body Myositis

Phase 3 · Completed · Novartis Pharmaceuticals

Associated genes

5 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

GNE0.73ACVR2B0.36CD99L20.12NT5C1A0.11CLEC9A0.02

Disease biology

1 match

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Activin receptor type-2Bvia ACVR2B0.36

Reference

Authoritative identity, definition & identifiers.

Synonyms

IBM, Sporadic Inclusion Body Myositis, sIBM, sporadic inclusion body myositis, Ibm, inflammatory myopathy

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.